374Water Inc. (filed as PowerVerde, Inc.) — Q2 2017 Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2017. The filing identifies the registrant as PowerVerde, Inc.; the request metadata identifies 374Water Inc. The financial statements are unaudited and cover PowerVerde and its wholly owned subsidiary.
Business context
The company was developing and commercializing clean-energy electric power generation systems, but none of its planned principal operations had commenced. All reported revenue came from legacy Biotech intellectual-property royalties unrelated to the planned clean-energy business. The royalty agreement generating all revenue since 2012 expires in March 2018.
Financial highlights
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Royalty revenue | $168,548 | $187,304 | $339,799 | $327,956 |
| Research and development expense | $46,732 | $46,730 | $94,389 | $104,455 |
| General and administrative expense | $56,455 | $120,802 | $114,898 | $207,113 |
| Income from operations | $65,361 | $19,772 | $130,512 | $16,389 |
| Net income (loss) | $57,219 | $5,897 | $112,425 | $(12,171) |
| Net income (loss) per share | $0.002 | $0.000 | $0.003 | $(0.000) |
Calculated operating margins were approximately 38.8% in Q2 2017 and 38.9% for the first six months of 2017. Net margins were approximately 34.0% and 33.1%, respectively. These margins reflect royalty revenue and are not indicative of commercial clean-energy operations.
- Cash flow: Six-month operating cash flow was $133,945 versus $99,998 in the prior-year period. Financing cash use was $125,000, consisting of principal payments to related parties. Net cash increased by $8,945 to $13,731.
- Liquidity: Working-capital deficit improved to $141,472 from $272,120 at December 31, 2016. June 30 cash was $13,731, accounts receivable were $168,548, and current liabilities were $369,720.
- Debt: Notes payable to related parties were $300,000 at June 30, 2017. The notes bear 10% interest and were secured by Biotech royalty receivables. Payments of $100,000 in April and $100,000 in July reduced the remaining principal to $200,000 in July 2017, due September 30, 2017.
- Capital structure: 31,750,106 common shares were outstanding. The company also had 4,175,000 outstanding warrants and 5,750,500 outstanding options, which were excluded from diluted share calculations because their effect was anti-dilutive.
Material changes versus prior comparable periods
- Q2 royalty revenue declined approximately 10.0%, while six-month royalty revenue increased approximately 3.6%.
- Q2 general and administrative expense decreased $64,347, primarily because the prior-year period included warrants issued to a stockholder.
- Six-month general and administrative expense decreased $92,215, or 44.5%, primarily because stock-based compensation fell from $72,000 to zero.
- Six-month research and development expense decreased $10,066, or 9.6%, as the company was testing rather than building new generator systems.
- The company moved from a six-month net loss of $12,171 in 2016 to net income of $112,425 in 2017, primarily due to lower operating and interest expenses.
- Accounts payable and accrued expenses declined to $69,720 from $79,073, and related-party notes declined to $300,000 from $425,000 at year-end 2016.
Guidance, outlook, risks and unusual items
- Management expected 2017 Biotech IP revenue to approximate 2016 levels, but stated that achievement was not assured.
- The company stated that it needed to raise substantial additional debt or equity capital to fund operations and might be forced to cease operations if financing could not be obtained.
- The going-concern risk is significant: the royalty contract expires in March 2018, and the company had no established replacement source of working capital or material operating revenue.
- Management intended to direct most 2017 royalty receipts toward the secured related-party notes, reduce salary and consulting expenses, and begin generating revenue from part-time skilled manufacturing services.
- The Helidyne license required purchases of two expanders totaling $50,000. The company had paid $38,750 but stopped further payments because Helidyne allegedly failed to perform; the ultimate resolution was uncertain.
- The company committed to a 3% Helidyne sales royalty, subject to a minimum annual royalty beginning upon commercialization or three years after the agreement date.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Confirm the registrant identity and corporate-name history, because the filing is for PowerVerde, Inc., while the request identifies 374Water Inc.
- Verify whether the $200,000 related-party note due September 30, 2017 was repaid, refinanced, or extended after the filing date.
- Assess the likelihood of renewing or replacing the Biotech royalty agreement before its March 2018 expiration.
- Review subsequent financing, operating revenue, and liquidity developments because June 30 cash was only $13,731 and the company disclosed substantial funding needs.
- Evaluate the status and recoverability of the $38,750 Helidyne-related prepaid amount and the company’s clean-energy commercialization plans.
- Consider dilution from 4,175,000 warrants and 5,750,500 options relative to the 31,750,106 shares outstanding.